- Fragile X
- Treatment & Intervention
- Support the NFXF
Seaside Therapeutics is studying the science of the brain and working to deliver treatments that improve the underlying causes of developmental disorders like Fragile X syndrome. Right now, Seaside is testing an investigational medicine called STX209 (arbaclofen) for individuals with Fragile X syndrome with social impairment. Thanks to the dedication and efforts of families, one of the clinical trials is almost complete.
We are reaching out to you because you may be a caregiver to a person with Fragile X syndrome and your family member may be eligible for the next study, the Harbor-C trial.
This trial is 70% completed and your family’s participation in this clinical trial can help drive this study to completion, furthering the advancement of new potential treatments for Fragile X syndrome.
Please go to www.harbortrial.com to learn more about this clinical study and consider contacting the most convenient clinical study site to your home to inquire further. For your convenience, we have included the list of clinical study sites on the below.
Social impairment seen in people with Fragile X syndrome can appear in many different ways. If your family member shows any of the following behaviors, or any others that limit their ability to form social connections (compared to typically developing children or adults), he or she may be eligible to participate in the Harbor Trials:
The Harbor Trials are designed to test the safety and effectiveness of the investigational drug STX209 (arbaclofen) versus placebo (inactive pills) in improving social function in people with Fragile X syndrome. Eligible participants will receive up to 2 months of treatment with the study drug (STX209 or placebo) and can continue on STX209 in a long-term follow up study. Travel cost reimbursement is available.
This study is sponsored by Seaside Therapeutics. 27 sites in the U.S. are currently enrolling. Additional information may be found on www.harbortrial.com or www.clinicaltrials.gov (references # NCT01282268 and NCT01325220).
To learn more about participating in the Harbor-C trial, please contact a clinical study coordinator at the clinical site nearest you.
Miller Children’s Hospital
Long Beach, CA
Study Coordinator: Nan O’Donnell
Psychiatric Associates of San Diego
San Diego, CA
Study Coordinator: Christine Moloney
University of California-Davis, M.I.N.D. Institute
Study Coordinator: Lindsey Partington
University of Miami, Miller
Study Coordinator: Elsa Salazar
Lake Mary Pediatrics
Orange City, FL
Study Coordinator: Heidi Andersen
Emory University School of Medicine, Division of Medical Genetics
Study Coordinator: Heather Clark
Rush University Medical Center
Study Coordinator: Shaguna Mathur
University of Kansas Medical
Kansas City, KS
Study Coordinator: Phyllis Young
Kennedy Krieger Institute
Study Coordinator: Kennedy Krieger, Victor Talisa
University of Massachusetts
Study Coordinator: Kara Manchester
Children’s Hospital of
Mount Sinai School of Medicine
New York, NY
Study Coordinator: Lauren Bush
NYS Institute of Basic Research in Developmental Disabilities
Staten Island, NY
Study Coordinator: Angelo Porto
Cincinnati Children’s Hospital (Coming Soon)
University of Oklahoma, Physician’s Child Study Center
Oklahoma City, OK
Study Coordinator: Lora Tusing
Suburban Research Associates /Associates / Elwyn Genetics
Study Coordinator: Maureen O’Donnell
(610) 891-9024 ext. 103
Greenwood Genetics Center (
Study Coordinator: Jessica Smith
Children’s Medical Center (
Red Oaks Psychiatry Associates, P.A.
Study Coordinator: Elissa Molloy
Texas Children’s Hospital
Study Coordinator: Brenda Noggy
Road Runner Research
San Antonio, TX
Study Coordinator: Katie Johanningmeier
Seattle Children’s Hospital
Study Coordinator: Denise Ward